George Scangos made a surprising shift when the former Biogen CEO left the world of big biotech to lead an infectious disease-focused start-up. Vir Biotechnology Inc. emerged in early 2017 with $150m and quickly brought its fundraising total later that year to more than $500m. The company went public late last year and Vir’s participation in the search for a coronavirus treatment has thrust the company into the spotlight in the last month, and elevated Scangos’s profile once again since he’s also leading BIO’s outreach to biotech firms to help get their coronavirus ideas from concept to clinical trials.
[Sidebar#SC099712]
